{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:10:45Z","timestamp":1789506645672,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031031","name":"Kinderspital Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128917","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:40:02Z","timestamp":1784922002000},"page":"128917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Characterization of vaccine viremia, attenuation reversion, and safety: Combined results from the TAK-003 dengue vaccine clinical development program"],"prefix":"10.1016","volume":"88","author":[{"given":"Vianney","family":"Tricou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Saez-Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pope","family":"Kosalaraksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Reynales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukiat","family":"Sirivichayakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa","family":"Borja-Tabora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny G.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley J.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Mandaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Roubinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuri","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Livengood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibadas","family":"Biswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7446","key":"10.1016\/j.vaccine.2026.128917_bb0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128917_bb0010","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.3390\/v14112575","article-title":"Immune-mediated pathogenesis in dengue virus infection","volume":"14","author":"Khanam","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128917_bb0015","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128917_bb0020","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128917_bb0025","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128917_bb0030","author":"European Medicines Agency"},{"issue":"21","key":"10.1016\/j.vaccine.2026.128917_bb0035","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"77","author":"Huang","year":"2003","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128917_bb0040","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.vaccine.2005.09.029","article-title":"Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults","volume":"24","author":"Kitchener","year":"2006","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2026.128917_bb0045","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128917_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000617","article-title":"Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006","volume":"4","author":"Fried","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128917_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154760","article-title":"Meta-analysis of dengue severity during infection by different dengue virus serotypes in primary and secondary infections","volume":"11","author":"Soo","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2026.128917_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2017.00317","article-title":"Global epidemiology of dengue outbreaks in 1990-2015: a systematic review and meta-analysis","volume":"7","author":"Guo","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"issue":"27","key":"10.1016\/j.vaccine.2026.128917_bb0065","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/j.vaccine.2018.05.028","article-title":"A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128917_bb0070","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J Infect Dis"},{"issue":"10234","key":"10.1016\/j.vaccine.2026.128917_bb0075","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2\u201317 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128917_bb0080","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128917_bb0085","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2\u201317 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10234","key":"10.1016\/j.vaccine.2026.128917_bb0090","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128917_bb0095","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1128\/JVI.74.7.3011-3019.2000","article-title":"Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5\u2032 noncoding region and nonstructural proteins 1 and 3","volume":"74","author":"Butrapet","year":"2000","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128917_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jviromet.2005.06.019","article-title":"Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA","volume":"131","author":"Butrapet","year":"2006","journal-title":"J Virol Methods"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128917_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax)","volume":"7","author":"Huang","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128917_bb0110","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/vbz.2010.0150","article-title":"Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in Aedes aegypti is modulated by a mutation in the 5\u2032 untranslated region and amino acid substitutions in nonstructural proteins 1 and 3","volume":"11","author":"Brault","year":"2011","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128917_bb0115","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.4269\/ajtmh.17-0185","article-title":"Limited transmission potential of Takeda\u2019s tetravalent dengue vaccine candidate by Aedes albopictus","volume":"97","author":"Dietrich","year":"2017","journal-title":"Am J Trop Med Hyg"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128917_bb0120","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2011.11.072","article-title":"Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice","volume":"30","author":"Brewoo","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128917_bb0125","doi-asserted-by":"crossref","first-page":"978","DOI":"10.4269\/ajtmh.2011.10-0592","article-title":"Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in cynomolgus macaques","volume":"84","author":"Osorio","year":"2011","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128917_bb0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128917_bb0135","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1006\/viro.1997.8500","article-title":"Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53","volume":"230","author":"Kinney","year":"1997","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128917_bb0140","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128917_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/v16101603","article-title":"Exploring dengue infection in a vaccinated individual: preliminary molecular diagnosis and sequencing insights","volume":"16","author":"Adelino","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128917_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2024.102782","article-title":"A case report on symptomatic disease caused by serotype 4 vaccine virus following tetravalent anti-dengue vaccination","volume":"62","author":"Oliveira","year":"2024","journal-title":"Travel Med Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128917_bb0155","doi-asserted-by":"crossref","first-page":"taaf091","DOI":"10.1093\/jtm\/taaf091","article-title":"Qdenga-induced dengue caused by minor DENV-2 subvariant(s) in the vaccine, with two amino acid substitutions in the E protein","volume":"32","author":"Pettersson","year":"2025","journal-title":"J Travel Med"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128917_bb0160","doi-asserted-by":"crossref","first-page":"e1214","DOI":"10.1093\/infdis\/jiae222","article-title":"Efficacy and safety of a tetravalent dengue vaccine (TAK-003) in children with prior Japanese encephalitis or yellow fever vaccination","volume":"230","author":"Sirivichayakul","year":"2024","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128917_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-00836-w","article-title":"Immune response induced by standard and fractional doses of 17DD yellow fever vaccine","volume":"9","author":"Abdala-Torres","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128917_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2024.103719","article-title":"Safety of the yellow fever vaccine in people living with HIV: a longitudinal study exploring post-vaccination viremia and hematological and liver kinetics","volume":"28","author":"Motta","year":"2024","journal-title":"Braz J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128917_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005219","article-title":"CD4\/CD8 ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients","volume":"10","author":"Avelino-Silva","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128917_bb0180","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1073\/pnas.1500475112","article-title":"Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination","volume":"112","author":"Akondy","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128917_bb0185","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2019.11.061","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: a phase 2, double-blind, randomised, controlled trial","volume":"38","author":"Tricou","year":"2020","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128917_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107617","article-title":"A non-structural 1 protein G53D substitution attenuates a clinically tested live dengue vaccine","volume":"31","author":"Choy","year":"2020","journal-title":"Cell Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:34:08Z","timestamp":1789504448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"alternative-id":["S0264410X26007267"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128917","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of vaccine viremia, attenuation reversion, and safety: Combined results from the TAK-003 dengue vaccine clinical development program","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Takeda Pharmaceuticals International AG. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128917"}}